Parabilis Medicines, Inc. · NASDAQ:PBLS
Parabilis Medicines — Earnings Presentation (August 2026)
32 slides from Parabilis Medicines's earnings presentation, Aug 13, 2026
Slide 1: Creating Extraordinary Medicines
Creating Extraordinary Medicines Drugging Previously Undruggable Intracellular Drivers of Serious Diseases August 2026
Slide 2: Forward-looking statements & disclaimer
Forward-looking statements & disclaimer PARABILIS MEDICINES This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words "anticipate," "believe," "continue,"
Slide 3: From platform breakthrough to advancing unique Helicon medicines
2015: Company founded; built on15 years of α-helix research at Harvard’s Verdine Lab to drug the “undruggables” 2024: Platform expansion into targeted protein degradation to further broaden pipeline 2018: First successful de novo hit discovery screen on the Helicon™ platform 2021: First in vivo-acti
Slide 4: Led by an experienced leadership team and Board
Led by an experienced leadership team and Board 4 Mathai Mammen, M.D., Ph.D. Chairman, Chief Executive Officer & President Kristen Stants Chief People Officer John McGee, Ph.D. Scientific Co-Founder and EVP, Head of Platform Fawzi Benzaghou, M.D. Chief Medical Officer BOARD OF DIRECTORS Mathai Mamme
Slide 5: Uniquely positioned to deliver near-term catalysts and long-term impact
Uniquely positioned to deliver near-term catalysts and long-term impact Advancing zolucatetide toward Phase 3 registrational study in desmoid tumors (1H 2027) with value-creating catalysts in 2026-2027 and beyond Targeting a multi-billion-dollar opportunity that also spans FAP, ACP, and other Wnt/ β
Slide 6: Our pipeline of differentiated Helicon therapeutic candidates
Our pipeline of differentiated Helicon therapeutic candidates PARABILIS MEDICINES PROGRAMS INDICATIONS DISCOVERY IND- ENABLING PHASE 1 PHASE 2 PHASE 3 ANTICIPATED UPCOMING MILESTONES Zolucatetide β-catenin:TCF Inhibitor Desmoid Tumors Maturing Phase 1/2 data Q4 2026 Phase 3 initiation 1H 2027 Famili
Slide 7: Helicons: Redefining what is druggable inside a cell
Helicons: Redefining what is druggable inside a cell Antibody-like control of disease-driving intracellular targets The Challenge: Undruggable Biology Our Solution: Helicons Stabilized α-helical peptides combine the precision of antibodies with the intracellular access and tunability of small molecu
Slide 8: Zolucatetide: The first and only β-catenin:TCF inhibitor
PARABILIS MEDICINES Zolucatetide: The first and only β-catenin:TCF inhibitor Target previously undruggable for decades present in over 10% of tumors across a range of tumor types Zolucatetide acts downstream of β-catenin or APC mutations zolucatetide Pursuing a Pipeline-in-a-Product Strategy for Zol
Slide 9: Desmoid Tumors: Locally invasive tumors with chronic, life-altering burden
Desmoid Tumors: Locally invasive tumors with chronic, life-altering burden Therapy with improved efficacy, tolerability and time to response could significantly expand market opportunity Sizable, chronic patient population Estimated 11K patients actively managed in the U.S. and 30K prevalent populat
Slide 10: Zolucatetide in Desmoid: Data supports advancing to registrational study
Zolucatetide in Desmoid: Data supports advancing to registrational study 25 Response-Evaluable* Patients (All data as of Feb 16, 2026) 100% DCR: Stable disease or better across all patients and all dose levels 74% ORR including one CR: 14 out of 19 patients with ≥2 post-baseline scans responded per
Slide 11: Zolucatetide in Desmoid: Data supports advancing to registrational study
Zolucatetide in Desmoid: Data supports advancing to registrational study One scan received after cut-off date CR: complete response; DL: dose level; PR: partial response; QW: weekly dosing; Q2W: every other week dosing; GSI: gamma-secretase inhibitor 38 patients dosed across dose escalation and dose
Slide 12: Zolucatetide in Desmoid: Volumetric data reinforces speed of response
Zolucatetide in Desmoid: Volumetric data reinforces speed of response and dose dependence RECIST 1.1 per Investigator Volumetric per Central Reader Preliminary data from EDC as of Oct 27, 2025, one scan provided after the cut-off date (Oct 31, 2025) 900 mg 450 mg 150 mg 900 mg 450 mg 150 mg 900 mg 4
Slide 13: Safety and tolerability as of Feb 16, 2026 data cut-off
Safety and tolerability as of Feb 16, 2026 data cut-off: Tolerability matters greatly for desmoid patients who are otherwise active and healthy Skin, gastrointestinal (GI), and ovarian/reproductive toxicities are common issues seen with currently available therapies At the dose levels where we have
Slide 14: Zolucatetide in Desmoid: Well-tolerated safety profile
Zolucatetide in Desmoid: Well-tolerated safety profile *Includes blood bilirubin increased; ** Includes blood sodium decreased; ^Grade 3 hyperbilirubinemia based on data error - corrected to Grade 2 after data cut date; #N=1 Grade 3 AST increase occurred prior to data cut; current entry is a data en
Slide 15: Phase 3 trial designed for label superiority and market differentiation
Placebo Zolucatetide Zolucatetide in Desmoid: Phase 3 trial designed for label superiority and market differentiation Treatment-naïve, recurrent, or refractory patients with desmoid tumor Study Population Study design for alignment with the FDA, with engagement planned for Q4 2026: Broad study popul
Slide 16: Familial Adenomatous Polyposis (FAP): driven by APC mutations
Familial Adenomatous Polyposis (FAP): 100% driven by APC mutations, causing polyp growth and inevitable progression to CRC if not removed Shared β-catenin biology and overlapping patient populations with desmoid Approximately 10% of patients with desmoid tumor have FAP Approximately 3% of FAP patien
Slide 17: FAP: Patients face a lifetime of disease burden with no approved drug therapy
FAP: Patients face a lifetime of disease burden and fear with no approved drug therapy Childhood and teens: Active surveillance >34K patient prevalence in US1 Diagnosed via family history, or de novo in ~30% of cases Colonoscopies begin around age of 10-15 Near-inevitable progression to CRC if polyp
Slide 18: Zolucatetide in FAP: Case Study #1
Zolucatetide in FAP: Potential to reduce pre-cancerous polyp burden Case Study #1 Strong clinical response in desmoid tumor PR at Week 16; -52% at Week 60 Patient dosed ~8 months at DL2 Q2W (as of scan on Oct 21, 2025) Patient remains on study at DL2 Q2W Desmoid patient with FAP enrolled in ongoing
Slide 19: Zolucatetide in FAP: Case Study #2
Zolucatetide in FAP: Potential to reduce pre-cancerous polyp burden Case Study #2 Recent treatment start for desmoid Began dosing at DL4 QW on Jan 22, 2026 Week 8 scan of desmoid tumor showed stable disease Remains on treatment at DL4 Q2W per protocol Desmoid patient with FAP enrolled in ongoing Pha
Slide 20: Adamantinomatous Craniopharyngioma (ACP): debilitating chronic disease
Adamantinomatous Craniopharyngioma (ACP): A debilitating, chronic disease with significant morbidity and no approved systemic therapy A lifelong disease driven by a single acquired mutation Conservative estimate of 5K-9K patients in the US1 Estimated 620 new CP US cases annually; ACP is the majority
Slide 21: Zolucatetide in ACP: Tumor reductions observed in 3 patients
Baseline Week 16 Patient 3: Partial response of -48% at week 16 (confirmed PR) Baseline Week 24 Patient 2: Has maintained stable disease for over 48 weeks, with a best tumor reduction of -19.2%; patient remains on study since initial dosing in August 2024 Baseline Week 8 Patient 1: Partial response
Slide 22: Zolucatetide in HCC: Single-patient clinical activity
Zolucatetide in HCC: Single-patient clinical activity consistent with expected β-catenin biology Case study Heavily pre-treated HCC patient with history of cirrhosis 4 pathogenic mutations (incl. β-catenin), 4 prior lines of therapy Week 8: -33% (PR) Baseline Clinical course on zolucatetide Patient
Slide 23: Zolucatetide in Rare Tumors: Responses in multiple Wnt/β-catenin-driven tumor types
Zolucatetide in Rare Tumors: Responses in multiple Wnt/β-catenin-driven tumor types highlights opportunity for a tumor-agnostic development pathway Data in Non-CRC Patients with Tumors of Low Genomic Complexity (pathogenic mutations ≤ 4*) 20 RECIST 1.1 responses, including one complete response (as
Slide 24: Building a lasting β-catenin franchise
Building a lasting β-catenin franchise with a relentless focus on patient impact PARABILIS MEDICINES β-catenin Franchise Advance β-catenin degraders as next-gen therapeutics where the approach may help further enhance efficacy, tolerability and convenience; expect to initiate IND-enabling activities
Slide 25: ERG Degrader: Potential first-in-class ERG degrader
ERG Degrader: Potential first-in-class ERG degrader targeting a long-recognized, yet historically undruggable, cancer driver PARABILIS MEDICINES Why is ERG a critical target to drug? TMPRSS2:ERG is the most prevalent genomic alteration in prostate cancer, present in 40-50% of the patients AR drives
Slide 26: ERG Degrader: Dose-dependent single-agent anti-tumor activity
ERG Degrader: Dose-dependent, single-agent anti-tumor activity in ERG-fusion models; synergy in combination with enzalutamide PARABILIS MEDICINES 95% TGI IHC-based ERG detection VCaP Xenograft Efficacy: ERG-fusion+, mCRPC AR amplified Helicon Vehicle 200x 200x Patient Derived Xenograft Efficacy: ERG
Slide 27: Allosteric ARON Degrader: Differentiated target
Allosteric ARON Degrader: Differentiated target with the potential to combine with standard of care and overcome resistance PARABILIS MEDICINES Why target the “ON” form of AR allosterically? All current approved AR-targeting therapies bind to the AROFF conformation mCRPC patients develop resistance
Slide 28: Allosteric ARON Degrader: Early signals of single-agent activity
PARABILIS MEDICINES Allosteric ARON Degrader: Early signals of single-agent activity and additivity in combination with enzalutamide Preclinical data from in vivo and in vitro AR amplified VCaP models Single agent anti-tumor activity in VCaP CDX model Combination additivity with enzalutamide in vitr
Slide 29: Helicon Platform: Fully integrated and AI-enabled
Helicon Platform: Fully integrated and AI-enabled Repeatable, scalable, and hard to replicate Enabled by a decade of high-volume proprietary data generation AI models trained on proprietary in-house data, proprietary industry leading complex peptide synthesis Extensive platform IP and accumulated kn
Slide 30: Differentiated Building Blocks Reach a Broader Design Space
Differentiated Building Blocks Reach a Broader Design Space A DMTA Cycle Measured in Weeks Automated Peptide Synthesis at a Scale Rare Outside Pharma 12 automated peptide synthesizers CEM Liberty Blue Syro II 2-week synthesis turnaround time ~90,000 singletons synthesized 200,000+ assay data points
Slide 31: Regeneron Collaboration: Expanding our Helicon platform
Regeneron Collaboration: Expanding our Helicon platform into new therapeutic areas and modalities with strong deal economics Antibody-Helicon Conjugates Unlocks a novel class of Helicon therapeutics targeting historically undruggable and challenging intracellular targets via antibody-Helicon conjuga
Slide 32: Strong balance sheet supports our path to key value-creating milestones
Strong balance sheet supports our path to key value-creating milestones $1.1 billion in cash, cash equivalents, and marketable securities as of June 30, 2026 $770.5 million IPO completed in June 2026 Expected cash runway into 2030 PARABILIS MEDICINES Zolucatetide Preclinical Pipeline Desmoid tumors
Parabilis Medicines — Earnings Presentation (August 2026) on 6ix